# A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency

> **NCT04633057** · PHASE3 · COMPLETED · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 168 (actual)

## Conditions studied

- Pediatric Growth Hormone Deficiency

## Interventions

- **DRUG:** TJ101
- **DRUG:** NordiFlex

## Key facts

- **NCT ID:** NCT04633057
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-25
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04633057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04633057, "A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04633057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*